Diabetes

Report: First of new class of drugs for diabetes shown successful

Published in Obesity and Diabetes Week, July 5th, 2004

Exenatide, the first of a new class of drugs for type 2 diabetes, was shown to reduce blood glucose (sugar) and body weight and was associated with improvement in markers of beta cell function, according to a report at the American Diabetes Association's 64th annual scientific sessions.

"Because exenatide has multiple underlying antidiabetes actions - as well as the ability to promote weight loss, which is often important for people with type 2 diabetes - it holds the potential to be a pivotally important drug in diabetes care," said Ralph DeFronzo, MD, professor of medicine and chief of the diabetes division, University of Texas Health Science Center, San Antonio,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry